CDC's RSV vaccine recommendations from Pfizer and GSK face review by HHS advisor William "Reyn" Archer III. Read more here.

GSK on Wednesday said it was "well positioned" to absorb potential U.S. pharmaceutical tariffs, citing AI-driven cost cuts ...

GSK plc's stock price has significantly outperformed the healthcare sector this year, supported by its healthy Q1 2025 ...

U.S.-listed shares of GSK are gaining in intraday trading Wednesday after the British pharma giant posted ...

Uncertainty continues to hang over the latest round of financial results and forecasts for companies both big and small as ...

GSK Plc reported better-than-expected profit in the first quarter as sales from its asthma and HIV drugs offset a lackluster vaccine performance. The UK drugmaker’s shares surged after it ...

As GSK weathers the storm of sinking vaccine sales and gears up for key launches in its specialty medicines sector, the British drug giant feels prepared for any challenges that U.S. drug import ...

(Reuters) - GSK on Wednesday said it was "well positioned" to absorb potential U.S. pharmaceutical tariffs, citing AI-driven cost cuts and dual sourcing for its medicines, but offered few details.

GSK is 'well positioned' to deal with the potential implications of any new US tariffs on pharma imports, the group said on Wednesday. President Donald Trump slapped a 10 per cent baseline ...

Royalty Income for 2025: Expected to be GBP 750 to 800 million. GSK PLC (NYSE:GSK) reported a 4% increase in group sales and a 5% rise in operating profit, demonstrating the strength and resilience of ...